

Remarks


Claims 56-69 are pending in the subject application. By this Amendment, Applicants have amended the title of the subject application. Applicants hereby reaffirm the election to prosecute the invention of Group I (claims 56-59), without traverse. As the species, Applicants hereby elect DF200 as the species of the isolated antibody; IL-2 as the additional component; a detectable moiety; and the KIR receptors bind to KIR2DL1 and KIR2DL2/3 and neutralizes KIR mediated inhibition of NK cell cytotoxicity.

By way of this amendment, claims 70-80 have been added (support for the new claims may be found, for example, in previously presented claim 56. Claims 56-69 have been canceled. Accordingly, claims 70-80 are currently before the Examiner and read on the elected invention. Favorable consideration of the pending claims is respectfully requested.

Applicants believe that the pending claims are in condition for allowance and such action is respectfully requested.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/sl